CMV retinitis (AIDS)
Opportunistic infection · Ophthalmology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Reactivation CMV end-organ disease of the retina in advanced HIV (CD4 usually <50). Progressive necrotising retinitis causes irreversible vision loss; may accompany systemic CMV (colitis, oesophagitis, encephalitis). A sight-threatening, AIDS-defining emergency - the ED job is same-day ophthalmology + starting systemic therapy.
Red flags
- Macular/central lesion or lesion adjacent to optic nerve (immediate sight threat)
- Rapidly progressive vision loss, new floaters or field defect
- Bilateral disease
- Features of systemic CMV (dysphagia, colitis, encephalitis)
- Retinal detachment
Assessment
Differential diagnosis
- HIV retinopathy (cotton-wool spots)
- Toxoplasma chorioretinitis
- Ocular syphilis
- Acute retinal necrosis (HSV/VZV)
- Candida/fungal endophthalmitis
- Immune recovery uveitis (IRIS)
Investigations
- Urgent dilated fundoscopy by ophthalmology (yellow-white retinal infiltrates + haemorrhage, 'brushfire/pizza-pie')
- CD4 count + HIV viral load
- Assess for extraocular CMV (colitis, oesophagitis, encephalitis)
- CMV PCR blood ± vitreous (helps resistance assessment)
- Baseline U&E/eGFR, FBC, electrolytes before antivirals
Management
- Urgent (same-day) ophthalmology referral + dilated exam
- Decide if immediately sight-threatening: lesion <1500 microns from fovea or adjacent to optic nerve head
- Sight-threatening -> intravitreal injection PLUS systemic therapy; not sight-threatening -> systemic therapy alone
- Check renal function before foscarnet/cidofovir; check ANC/platelets before ganciclovir
- Screen for other CMV end-organ disease
- Start/optimise ART (usually ~2 weeks after CMV therapy; immediately if poor follow-up); monitor for immune recovery uveitis/IRIS
Drugs & doses
Oral valganciclovir 900 mg PO BID with food x14-21 days (induction), then 900 mg PO once daily (maintenance) - preferred systemic agent
IV ganciclovir 5 mg/kg/dose q12h (induction); maintenance 5 mg/kg/day - if oral not tolerated; avoid if ANC <500 or platelets <20,000
IV foscarnet 60 mg/kg/dose q8h OR 90 mg/kg/dose q12h (induction); maintenance 90-120 mg/kg/day - renal/electrolyte toxicity, needs hydration
Intravitreal ganciclovir 2.5 mg in 0.05 mL weekly x2-3, OR intravitreal foscarnet 2.4 mg/injection twice weekly (1-4 doses over 7-14 days) - for immediate sight-threatening disease, WITH systemic therapy (specialist)
Cidofovir 5 mg/kg IV weekly x2 then 5 mg/kg every other week + IV saline + oral probenecid - 3rd-line; contraindicated if Cr >1.5 mg/dL, eGFR <=55, urine protein >=100 mg/dL, or sulfa allergy
Relapse/salvage: IV ganciclovir + IV foscarnet combination (specialist)
Disposition
Urgent same-day ophthalmology; admit for IV induction or systemic CMV disease; HIV/ID for ART; close ophthalmology follow-up for monitoring and IRIS.
Complications & pitfalls
- Blindness
- Retinal detachment
- Immune recovery uveitis / IRIS
- Contralateral eye or extraocular spread
- Drug toxicity (ganciclovir marrow suppression; foscarnet renal/electrolyte; cidofovir nephrotoxicity)
- Endophthalmitis/vitreous haemorrhage from intravitreal injections
Exam pearls
- CD4 almost always <50; AIDS-defining - do not delay ophthalmology
- Continue maintenance until retinitis quiescent, treated >=3 months AND CD4 >=100 for >=3-6 months; reinitiate if CD4 drops <100
- Ganciclovir implants are no longer manufactured
- Valganciclovir 900 mg gives drug exposure equivalent to IV ganciclovir 5 mg/kg
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.